180 related articles for article (PubMed ID: 17101741)
1. NXY-059 does not significantly interact with furosemide in healthy volunteers.
Strid S; Nilsson D; Borgå O; Wemer J; Grahnén A
J Clin Pharmacol; 2006 Dec; 46(12):1417-25. PubMed ID: 17101741
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects.
Wemer J; Cheng YF; Nilsson D; Reinholdsson I; Fransson B; Lanbeck Vallén K; Nyman L; Eriksson C; Björck S; Schulman S
Curr Med Res Opin; 2006 Sep; 22(9):1813-23. PubMed ID: 16968585
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
Cheng YF; Jiang J; Hu P; Reinholdsson I; Guo W; Asenblad N; Nilsson D
Clin Ther; 2008 Dec; 30(12):2342-53. PubMed ID: 19167593
[TBL] [Abstract][Full Text] [Related]
4. NXY-059 does not affect bleeding time in healthy volunteers: a randomized, double-blind, placebo-controlled, 3-period crossover phase I study.
Nilsson D; Wemer J; Cheng YF; Reinholdsson I; Englund G; Egberg N; Schulman S
J Clin Pharmacol; 2007 Feb; 47(2):264-72. PubMed ID: 17244778
[TBL] [Abstract][Full Text] [Related]
5. A phase 1, placebo-controlled, randomised, double-blind (within dose panels) study evaluating the safety, tolerability and pharmacokinetics of intravenous NXY-059 in Japanese subjects.
Watabe M; Cheng YF; Nilsson D; Itoh Y; Kumagai Y
Curr Med Res Opin; 2007 Aug; 23(8):1849-57. PubMed ID: 17605894
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
7. NXY-059 for the treatment of acute ischemic stroke.
Shuaib A; Lees KR; Lyden P; Grotta J; Davalos A; Davis SM; Diener HC; Ashwood T; Wasiewski WW; Emeribe U;
N Engl J Med; 2007 Aug; 357(6):562-71. PubMed ID: 17687131
[TBL] [Abstract][Full Text] [Related]
8. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.
Dormans TP; van Meyel JJ; Gerlag PG; Tan Y; Russel FG; Smits P
J Am Coll Cardiol; 1996 Aug; 28(2):376-82. PubMed ID: 8800113
[TBL] [Abstract][Full Text] [Related]
9. The comparison of the diuretic and natriuretic efficacy of continuous and bolus intravenous furosemide in patients with chronic kidney disease.
Sanjay S; Annigeri RA; Seshadri R; Rao BS; Prakash KC; Mani MK
Nephrology (Carlton); 2008 Jun; 13(3):247-50. PubMed ID: 18315706
[TBL] [Abstract][Full Text] [Related]
10. Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure.
Pivac N; Rumboldt Z; Sardelić S; Bagatin J; Polić S; Ljutić D; Naranca M; Capkun V
Int J Clin Pharmacol Res; 1998; 18(3):121-8. PubMed ID: 9825268
[TBL] [Abstract][Full Text] [Related]
11. Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial.
van der Voort PH; Boerma EC; Koopmans M; Zandberg M; de Ruiter J; Gerritsen RT; Egbers PH; Kingma WP; Kuiper MA
Crit Care Med; 2009 Feb; 37(2):533-8. PubMed ID: 19114909
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of NXY-059, a nitrone-based free radical trapping agent, in healthy young and elderly subjects.
Edenius C; Strid S; Borgå O; Breitholtz-Emanuelsson A; Vallén KL; Fransson B
J Stroke Cerebrovasc Dis; 2002; 11(1):34-42. PubMed ID: 17903853
[TBL] [Abstract][Full Text] [Related]
13. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
[TBL] [Abstract][Full Text] [Related]
14. Diuretic effects of subcutaneous furosemide in human volunteers: a randomized pilot study.
Verma AK; da Silva JH; Kuhl DR
Ann Pharmacother; 2004 Apr; 38(4):544-9. PubMed ID: 14982985
[TBL] [Abstract][Full Text] [Related]
15. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance.
Givertz MM; Massie BM; Fields TK; Pearson LL; Dittrich HC;
J Am Coll Cardiol; 2007 Oct; 50(16):1551-60. PubMed ID: 17936154
[TBL] [Abstract][Full Text] [Related]
16. Does furosemide prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-blinded prospective randomised trial.
Mahesh B; Yim B; Robson D; Pillai R; Ratnatunga C; Pigott D
Eur J Cardiothorac Surg; 2008 Mar; 33(3):370-6. PubMed ID: 18243724
[TBL] [Abstract][Full Text] [Related]
17. NXY-059: review of neuroprotective potential for acute stroke.
Fong JJ; Rhoney DH
Ann Pharmacother; 2006 Mar; 40(3):461-71. PubMed ID: 16507608
[TBL] [Abstract][Full Text] [Related]
18. Variable furosemide absorption and poor predictability of response in elderly patients.
Murray MD; Haag KM; Black PK; Hall SD; Brater DC
Pharmacotherapy; 1997; 17(1):98-106. PubMed ID: 9017769
[TBL] [Abstract][Full Text] [Related]
19. Pilot randomised double-blind controlled trial of high-dose spironolactone in critically ill patients receiving a frusemide infusion.
Apte Y; Bellomo R; Warrillow S; Goldsmith D; Gillies M; McGain F
Crit Care Resusc; 2008 Dec; 10(4):306-11. PubMed ID: 19049481
[TBL] [Abstract][Full Text] [Related]
20. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Circ Heart Fail; 2009 Nov; 2(6):532-40. PubMed ID: 19919977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
